Table S5 from The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients
B. Zheng, Lei Chen(Zhuzhou Central Hospital), Gao-Jing Liu, Fuming Sun(Dalian Minzu University), Qingzheng Zhang(Berry Oncology (China)), Guohong Deng(University of Groningen), Guo‐Qing Jiang(Yangzhou University), Jian Sun(Nanfang Hospital), Dan Zheng(Guizhou Cancer Hospital), Yujing Gao(Anhui University), Jie Xia(Zhejiang Normal University), He-Ping Hu(Second Military Medical University), Yanhang Gao(Jilin University), Jinlin Hou(Southern Medical University), Lan-Lan Ru, Yi-Nong Ye(First People's Hospital of Foshan), Rong Fan(University of Iowa), Yan-Long Yu(Chifeng University), Yin Wang(Shanxi Provincial Children's Hospital), Xiaolong Liu(Guilin University of Technology), Hui Wang(Shenzhen Third People’s Hospital), Jinming Chen(Guangdong Academy of Medical Sciences), Hao Wen(Xinjiang Medical University), Lutao Du(Shandong University), Yang Yuan(Qingdao University), Hongyang Wang(Second Military Medical University), Jingfeng Liu(Fujian Medical University), Jian Bai, Lin Wu(Berry Oncology (China)), Chunying Wang(Hebei Science and Technology Department), Fei Kong(Shanghai Jiao Tong University), Yingchao Wang(Tianjin Agricultural University), Min-Feng Liang(First People's Hospital of Foshan), Yun-Song Qian(University of Chinese Academy of Sciences), Feng Shen(Second Military Medical University), Chun-Xiu Zhong(Southern Medical University), Chuanxin Wang(Jilin University), Xiaotang Fan(Army Medical University), Jing Zhang(Yanshan University), Huadong Yan(Zhejiang Shuren University)
Cited by 0
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
<p>The Antibacterial Mechanism of Silver Nanoparticles and Its Application in Dentistry</p>
|International Journal of Nanomedicine|2020|1.6k
Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
|Cancer Cell|2016|1.2k